Accueil   Diary - News   All news Poxel presents new data

Poxel presents new data

18-week phase 2 study confirms imeglimin's unique profile with dual effect on improving insulin secrection and sensistivity


POXEL SA, a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, announced the presentation of data on its two lead pipeline programs at the World Congress on Insulin Resistance and Cardiovascular Disease (WCIRDC), which was hels last week in Los Angeles. On november 19th, the company presented clinical data and in depth analysis demonstrating Imeglimin's premium potiential as a novel type 2 diabetes monotherpay improving insulin secretion and insulin sensitivity in diabetic patients from an 18week phase 2 study.



Read the press release




By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to More details are available by clicking here I agree